Clinical Detection and Treatment of Benign and Malignant Pituitary Diseases

  • Dima L. Diab
  • Amir H. Hamrahian
Part of the Molecular Pathology Library book series (MPLB, volume 3)


The pituitary gland weighs about 0.5-1 g and is divided into an anterior and a posterior lobe. The pituitary gland sits in the sella turcica immediately behind and superior to the sphenoid sinus. Cavernous sinuses are located laterally on each side of the sella and include the internal carotid artery and cranial nerves III, IV, V1, V2, and VI. Magnetic resonance imaging (MRI) is the best method for visualization of hypothalamic-pituitary anatomy (Figure 17.1). Anterior pituitary hormones are regulated by hypothalamic releasing and inhibitory hormones as well as negative feedback action of the target glandular hormones at both the pituitary and hypothalamic levels (Table 17.1).


Pituitary Adenoma Dopamine Agonist Pituitary Tumor Cavernous Sinus Visual Field Defect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Melmed S, Kleinberg D. Anterior pituitary. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia: Saunders; 2003:177–279.Google Scholar
  2. 2.
    Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613–619.CrossRefPubMedGoogle Scholar
  3. 3.
    Gopan T, Toms SA. Symptomatic pituitary metastases from renal cell carcinoma. Pituitary. 2007;10(3):251–259.CrossRefPubMedGoogle Scholar
  4. 4.
    Melmed S. Update in pituitary disease. J Clin Endocrinol Metab. 2008;93:331–338.CrossRefPubMedGoogle Scholar
  5. 5.
    Powell M, Lightman S, Laws E. Management of Pituitary Tumors the Clinician’s Practical Guide. 2nd ed. Totowa: Humana; 2003.Google Scholar
  6. 6.
    Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65:265–273.CrossRefGoogle Scholar
  7. 7.
    Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29–38.CrossRefPubMedGoogle Scholar
  8. 8.
    Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. 2003;6:175–180.CrossRefPubMedGoogle Scholar
  9. 9.
    Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab. 2000;85:2068–2071.CrossRefPubMedGoogle Scholar
  10. 10.
    Bonadonna S, Doga M, Gola M, Mazziotti G, Giustina A. Diagnosis and treatment of acromegaly and its complications: consensus guidelines. J Endocrinol Invest. 2005;28:43–47.PubMedGoogle Scholar
  11. 11.
    Ezzat S, Serri O, Chik CL, et al. Canadian consensus guidelines for the diagnosis and management of acromegaly. Clin Invest Med. 2006;29:29–39.PubMedGoogle Scholar
  12. 12.
    Canibano C, Rodriguez NL, Saez C, et al. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J. 2007;26:2015–2028.CrossRefPubMedGoogle Scholar
  13. 13.
    Findling JW, Raff H. Cushing’s Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab. 2006;91:3746–3753.CrossRefPubMedGoogle Scholar
  14. 14.
    Giacomini D, Paez-Pereda M, Theodoropoulou M, et al. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology. 2006;147:247–256.CrossRefPubMedGoogle Scholar
  15. 15.
    Ness-Abramof R, Ishay A, Harel G, et al. TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature. Pituitary. 2007;10:307–310.CrossRefPubMedGoogle Scholar
  16. 16.
    Vance ML. Treatment of patients with a pituitary adenoma: one clinician’s experience. Neurosurg Focus. 2004;16:E1.CrossRefPubMedGoogle Scholar
  17. 17.
    Lubke D, Saeger W. Carcinomas of the pituitary: definition and review of the literature. Gen Diagn Pathol. 1995;141:81–92.PubMedGoogle Scholar
  18. 18.
    Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90:3089–3099.CrossRefPubMedGoogle Scholar
  19. 19.
    Max MB, Deck MD, Rottenberg DA. Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology. 1981;31:998–1002.PubMedGoogle Scholar
  20. 20.
    Serhal D, Weil RJ. Evaluation and management of pituitary incidentalomas. Cleve clin J Med. 2008;75(11):793–801.CrossRefPubMedGoogle Scholar
  21. 21.
    Schubiger O, Haller D. Metastases to the pituitary - hypothalamic axis. An MR study of 7 symptomatic patients. Neuroradiology. 1992;34:131–134.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Dima L. Diab
    • 1
  • Amir H. Hamrahian
    • 1
  1. 1.Department of EndocrinologyCleveland ClinicClevelandUSA

Personalised recommendations